Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Viral infectious illnesses represent a severe hazard to human health due to their widespread incidence worldwide. Among these ailments, the dengue virus (DENV) infection stands out. World Health Organization (WHO) estimates that DENV infection affects ~400 million people each year, with potentially fatal symptoms showing up in 1% of the cases. In several instances, academic and pharmaceutical researchers have conducted several pilot and clinical studies on a variety of topics, including viral epidemiology, structure and function analyses, infection source and route, therapeutic targets, vaccinations, and therapeutic drugs. Amongst Takeda, TAK-003, Sanofi, Dengvaxia®, and Butantan/NIH/Merck, Dengvaxia® (CYD-TDV) is the only licensed vaccination yet; however, the potential inhibitors are under development. The biology and evolution of DENVs are briefly discussed in this review, which also compiles the most recent studies on prospective antiviral targets and antiviral candidates. In conclusion, the triumphs and failures have influenced the development of anti-DENV medications, and the findings in this review article will stimulate more investigation.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.2174/0113862073244468230921050703 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Structural Dynamics of Dengue Virus UTRs and Their Cyclization.
Biophys J
September 2025
Department of Chemistry and Biochemistry, Alberta RNA Research and Training Institute, University of Lethbridge, 4401 University Drive, Lethbridge, AB, T1K 3M4, Canada; Li Ka Shing Institute of Virology, University of Alberta, Edmonton T6G 2E1, Alberta, Canada; Department of Microbiology, Immunology
The dengue virus (DENV) poses a significant threat to human health, accounting for approximately 400 million infections each year. Its genome features a circular structure that facilitates replication through long-range RNA-RNA interactions, utilizing cyclization sequences located in the untranslated regions (UTRs). To gain new insights into the organization of the DENV genome, we purified the 5' and 3' UTRs of DENV in vitro and examined their structural and binding properties using various biophysical techniques combined with computational methods.
View Article and Find Full Text PDFQdenga-induced dengue caused by minor DENV-2 subvariant(s) in the vaccine, with two amino acid substitutions in the E protein.
J Travel Med
September 2025
Public Health Agency of Sweden, Solna, Sweden.
We describe a Qdenga-induced DENV-2-infection in a Swedish traveler. Comparative sequencing suggests that the vaccine contained a small fraction of identical virus as detected in the patient, suggesting a selection of a DENV-2-substrain with unusual amino acid substitutions. Further research on selection of, and possible effects of, Qdenga-substrain-infections is warranted.
View Article and Find Full Text PDFDengue among immunocompromised patients: a systematic review and meta-analysis.
J Travel Med
September 2025
Vaccine Trial Centre, Faculty of Tropical Medicine, Mahidol University, Bangkok, Thailand.
Background: Although there is a rising trend in both dengue cases and immunocompromised conditions, there is limited research on how common severe dengue is in immunocompromised individuals. This data is key for those advising the ever-increasing numbers of immunocompromised travellers.
Methods: We conducted a systematic review and meta-analysis of studies reporting dengue frequency or outcomes in immunocompromised populations.
Rising tide of Vector-Borne Diseases in Europe - Surveillance, Clinical Awareness, and Public Health Preparedness.
Int J Infect Dis
September 2025
Division of Infection and Immunity, University College London, London, United Kingdom; NIHR Biomedical Research Centre, UCL Hospitals NHS Foundation Trust, London, NW3 OPQ, United Kingdom. Electronic address:
Managing Life-Threatening Complications of Dengue Fever in Two Sickle Cell Disease Patients: A Case Series.
Int J Infect Dis
September 2025
Service de Médicine et Chirurgie Pédiatrique, Centre Hospitalier de Cayenne, 3 Avenue Alexis Blaise, 97300 Cayenne, Guyane Française; Centre de référence de la drépanocytose, Centre Hospitalier de Cayenne, 3 Avenue Alexis Blaise, 97300 Cayenne, Guyane Française; UFR Santé Hyacinthe BASTARAUD
Patients with sickle cell disease (SCD) infected with dengue virus are at high risk of developing severe complications. However, the optimal management approach for this patient population remains unclear. We report two cases of dengue-associated multiorgan failure in adolescents with hemoglobin SC (HbSC) disease, both of whom recovered following structured symptomatic management.
View Article and Find Full Text PDF